Pendapatan operasional sadurunge ngurangi amortisasi: FibroBiologics, Inc. (FBLG)

FibroBiologics, Inc. (FBLG) lacks pricing power due to the absence of commercial sales and pending FDA decisions. EBITDA analytics demonstrate financial stability, with the indicator standing at 0.00. Business growth relies on the success of fibroblast therapy for sclerosis and patents. Stability is supported by diversified distribution of bio-raw materials under strict temperature control, which minimizes shortage risks.

FBLG: Bathi operasional EBITDA fibrobiologics.com 23.11.2025 - 12.11.2026

Ringkesan rincian data analitis FibroBiologics (FBLG)

- rega saham lan target rega konsensus:

Bagan rega FibroBiologics Inc.|FBLG - Bagan rega target

- indikator kapitalisasi bursa perusahaan:

Kapitalisasi pasar FibroBiologics|FBLG - Nilai Perusahaan

- data ekuitas miturut neraca:

Nilai Buku Saham FibroBiologics|FBLG - Kapitalisasi Buku|Kapitalisasi Pasar marang Nilai Buku fibrobiologics.com|FBLG - Total Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Utang marang Ekuitas FibroBiologics, Inc.|FBLG - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal FibroBiologics Inc.|FBLG - Utang perusahaan|Utang-utang marang nilai buku FibroBiologics|FBLG - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan FibroBiologics|Koefisien jangkoan perantara fibrobiologics.com

- informasi bathi lan kelipatan valuasi:

FBLG - Bathi resik perusahaan|Bathi resik sing dikarepake FibroBiologics, Inc.|FBLG - Rasio rega marang bathi|Rega marang bathi mangsa ngarep FibroBiologics Inc.|FBLG - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan FibroBiologics|FBLG - Bathi operasional EBITDA|Bathi resik saben saham sajroning taun lumaku FibroBiologics|FBLG - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan fibrobiologics.com|FBLG - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep FibroBiologics, Inc.

Analisis kabeh metrik perusahaan:FibroBiologics, Inc.

Produk sing diprodhuksi FibroBiologics Corp

This indicator tracks daily cash flow from core operations before debt obligations and tax payments, allowing for an assessment of the business's financial stability during periods of market volatility. Analysis of the underlying operating result before depreciation reflects the funding efficiency of current developments at FibroBiologics, Inc., which is critical during the technical modernization of production capacities to scale cellular products.

Karo sapa FibroBiologics, Inc. saingan

Mesoblast Pharma - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|LCTX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Pendapatan operasional sadurunge ngurangi amortisasi surrozen.com SRZN|CCEL: Bathi operasional EBITDA|Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi LGVN (Longeveron Inc)|BRTX (BioRestorative Therapies Inc) - Bathi operasional EBITDA|Creative Medical Technology Holdings Inc. (CELZ) - Pendapatan operasional sadurunge ngurangi amortisasi